What is the LungPRO™ cancer test?

LungPRO™ is a prognostic test  service for the Prediction of recurrence in early  stage Lung cancer.

LungPRO™ test service utilizes gene expression technology to identify biomarkers to distinguish the negative responder (patients who will have recurrence within five years after complete resection) from the positive responder following surgical treatment in early stage (Stages Ia and Ib) Non-Small Cell Lung Cancer (NSCLC) patients. The results obtained from comparing patient samples to the biomarker profile will empower oncologists to:

Predict the likely recurrence of cancer, thereby determining whether additional treatment is needed after complete resection.

Benefits of LungPRO

1. Predict likelihood of cancer recurrence
2. Reduce healthcare costs
3. Personalize the course of treatment